Team

Christopher Colecchi

Managing Director

Christopher Colecchi is the Managing Director of Broadview Ventures. He leads the Broadview investment team and operations, and coordinates the activities of Broadview’s Strategic Advisory Board. Chris also oversees the investment activities of Longview Ventures.

Previously, Chris was the Vice President for Research Ventures and Licensing at Partners Healthcare (now Mass General Brigham) – an integrated health system founded by the Harvard-affiliated Brigham and Women’s Hospital and Massachusetts General Hospital. In this role, Chris led business development, technology transfer, and commercialization activities and managed efforts to establish strategic alliances with the life sciences industries. He also created the Partners Innovation Fund – a venture capital fund that makes investments in early stage companies emerging from Mass General Brigham hospitals.

Earlier in his career, Chris was the Director of Clinical Trials and Industrial Relations for the Massachusetts General Hospital and Director of Clinical Monitoring for a clinical research organization at which he oversaw the set-up and management of multi-center, industry-sponsored clinical trials at several hundred sites throughout the U.S. and Canada. Within these roles, Chris worked directly with most of the major international pharmaceutical and biotechnology companies as well as many in the device arena.

Chris currently serves on the boards of Ground Fluor Pharma (Chairman), EP Sciences, and Aggamin. He previously served on the boards of CardiAQ (Acquired by Edwards Life Sciences), miRagen (NSDQ: MGEN), Cardero (now Epirium Bio), GI Windows, and InfoBionic.

Outside of Broadview, Chris serves as an advisory board member for the University of Massachusetts School of Public Health and Health Sciences. He is a board member of the Massachusetts Association for Mental Health and the Institute for Cardiovascular Research and Science founded by the Royal Brompton and the Liverpool Heart and Chest Hospitals.

Chris holds a B.A. from the College of the Holy Cross and an M.P.H. from the University of Massachusetts School of Public Health at Amherst.

Thomas Needham, MBA

Director, Head of the Biopharma Practice

Tom Needham, MBA, is a Director and Head of the Biopharmaceuticals practice at Broadview Ventures.

Tom shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.

Tom has 30 years of experience in venture capital, business development, corporate strategy, and C-suite executive management responsibilities in public and private life science companies. Tom currently serves on the boards of Basking Biosciences, including serving as Chairman (2020 thru 2023) and IsomAb, as well as holds board observer roles at Comanche Bio and HAYA Therapeutics. Previously, Tom represented Broadview on the board at Antag Therapeutics, Renovacor (NYSE: RCOR, acquired by Rocket Pharma), including serving as Renovacor’s Chairman (2019 thru 2021), and held board observer roles at NIDO Surgical (acquired), and Cardero Therapeutics (now Epirium Bio). Tom’s prior venture investment experience also includes working on Astex Pharmaceuticals (NASDAQ: ASTX, acquired by Otsuka), Enanta Pharmaceuticals (NASDAQ: ENTA), MD Everywhere (acquired by Marlin Equity Partners), Sirion Therapeutics (trade sale to Alcon and Bausch & Lomb) and Aegerion Pharmaceuticals (NASDAQ: AEGR).

Prior to joining Broadview Ventures, Tom was most recently Chief Business Officer at Merrimack Pharmaceuticals (Nasdaq: MACK) and Senior Vice President, Business Development at C4 Therapeutics (NASDAQ: CCCC). Prior to C4T, Tom spent 13 years as a venture capital investor, most recently as a Managing Director at Synthesis Capital, where he was involved in the management of two healthcare venture funds focused on investments in biotechnology, pharmaceuticals and medical technology. Prior to Synthesis, Tom was a Principal at Advent International, a global private equity firm, as a member of the healthcare venture capital deal team in Boston. Earlier in his career, Tom held Vice President of Business Development positions at private and public biotech companies, where he led the negotiation and closing of a number of strategic transactions, including R&D partnerships with global pharmaceutical companies, licensing and M&A transactions. Tom holds a B.A. from Bowdoin College and an MBA from Babson College’s F.W. Olin Graduate School of Business.

Eugene Braunwald, MD

EUGENE BRAUNWALD, M.D. is the Distinguished Hersey Professor of Medicine at Harvard Medical School, and the founding Chair of the TIMI Study Group at the Brigham and Women’s Hospital.

Dr. Braunwald received his medical training at New York University and completed his Medical Residency at the Johns Hopkins Hospital. He served as the first Chief of the Cardiology Branch and as Clinical Director of the National Heart, Lung and Blood Institute, founding Chairman of the Department of Medicine at the University of California, San Diego. From 1972 to 1996 he was Chairman of the Department of Medicine at the Brigham and Women’s Hospital. He was a founding trustee and Chief Academic Officer of Partners HealthCare System.

Dr. Braunwald’s first major paper was published in Circulation Research in July 1954, and he has been a major force in cardiology in the past sixty years. His early work focused on the control of ventricular function and he was the first to measure both left ventricular ejection fraction and left ventricular dp/dt in patients. His group showed the first neurohumoral defect in human heart failure, defined the pathophysiology of hypertrophic cardiomyopathy and demonstrated salvage of ischemic myocardium following coronary occlusion. They defined myocardial stunning and ventricular remodeling following myocardial infarction. For the past 35 years, he and his colleagues at the TIMI Study Group demonstrated improved patient survival with a patent coronary artery which led to the widely accepted “open artery hypotheses.” They were the first to show the benefit of preventing adverse remodeling of the infarcted ventricle with ACE inhibition. In the PROVE-IT TIMI 22 Trial, in 2004, they demonstrated the benefit of more intensive reduction of LDL in high risk coronary artery patients, which has changed practice guidelines and will favorably affect the lives of millions.

Dr. Braunwald has been an editor of Harrison’s Principles of Internal Medicine for 12 editions, and the founding editor of Heart Disease, now in its 11th Edition, the most influential textbooks in their fields.

Science Watch listed Dr. Braunwald as the most frequently cited author in Cardiology; he has an H index of 227. Based on his contributions, Dr. Braunwald has received numerous honors and awards including the Distinguished Scientist and Lifetime Achievement Awards of the American College of Cardiology, Research Achievement, and Herrick Awards of the American Heart Association, the Gold Medal of the European Society of Cardiology. He received an honorary Doctor of Science from the University of Oxford and is the recipient of honorary doctorates from twenty three other distinguished universities on three continents. The American College of Cardiology has established an annual lecture in his name. The European Society of Cardiology, Heart Failure Association has established an annual lecture in his name. Dr. Braunwald was the first cardiologist elected to the National Academy of Sciences of the United States. The living Nobel Prize winners in medicine voted Dr. Braunwald as “the person who has contributed the most to cardiology in recent years”.

Costantino Iadecola, MD

Costantino Iadecola, M.D.

Anne Parrish Titzell Professor of Neurology

Director and Chair, Feil Family Brain and Mind Research Institute

Weill Cornell Medical College, New York

Dr. Iadecola is a clinician-scientist who is an internationally recognized expert in the field of cerebrovascular diseases and dementia. Dr. Iadecola received an MD degree from the University of Rome, Italy, and completed Neurology Residencies both at the University of Rome and at New York Hospital-Cornell Medical Center, New York, NY.

After completing his training, Dr. Iadecola joined the Department of Neurology of the University of Minnesota, where he rose through the academic ranks serving as Professor and Vice-Chair for Research. In 2001, Dr. Iadecola was recruited back to Cornell as the G. C. Cotzias Distinguished Professor of Neurology and Neuroscience, and Director of the Division of Neurobiology. In 2012 Dr. Iadecola was appointed Anne Parrish Titzell Professor of Neurology and Director of the Feil Family Brain and Mind Research Institute, a new Department at Weill Cornell focused on basic and translational neuroscience research.

Dr. Iadecola’s research focuses on the basic mechanisms of neurovascular function and on the cellular and molecular alterations underlying ischemic brain injury, neurodegeneration and cognitive impairment. A pioneer in establishing the concept of Neurovascular Unit, Dr. Iadecola has championed the involvement of neurovascular dysfunction in neurodegenerative diseases, and the role of innate immunity and the microbiome in ischemic brain injury. He is active in several national and international research organizations and funding agencies, including the NIH, the American Heart Association (AHA) and the Alzheimer’s Association. He has been President (Chair) of the Scientific Advisory Committee of the Fondation Leducq and is an advisor to the several research consortia in the US and Europe. Dr. Iadecola has served as Editor or Editorial Board member for a number of journals including: Stroke, Journal of Neuroscience, Circulation research, and the Annals of Neurology.

Dr. Iadecola has received the McHenry Award from the American Academy of Neurology, two Jacob Javits Awards from the National Institutes of Health, the Willis Award-the highest honor in stroke research bestowed by the American Heart Association (AHA), the Zenith Fellow Award from the Alzheimer’s Association, the Excellence Award in Hypertension Research (Novartis) from the Hypertension Council of the AHA. In 2015, he was elected to the Association of American Physicians. In 2019 Dr. Iadecola was elected Distinguished Scientist by the AHA and in 2021 he received the AHA Basic Research Prize. In 2022 he received the Lifetime Achievement Award from the International Society of Cerebral Blood Flow and Metabolism. Since 2018, Clarivate Analytics listed Dr. Iadecola as one of world’s “Highly Cited Researchers” for ranking in the top one percent of the most-cited authors in the field of neuroscience and behavioral sciences. His career was recently profiled in Nature Neuroscience (https://rdcu.be/drhr2).

Joseph Loscalzo, MD, PhD

Joseph Loscalzo, M.D., Ph.D.

Samuel A. Levine Professor of Medicine

Hersey Distinguished Professor of the Theory and Practice of Medicine

Harvard Medical School

Physician-in-Chief Emeritus

Brigham and Women’s Hospital

Boston, Massachusetts

Dr. Joseph Loscalzo is currently the Samuel A. Levine Professor of Medicine and Hersey Distinguished Professor of the Theory and Practice of Medicine at Harvard Medical School as well as Physician-in-Chief Emeritus and former Chair of the Department of Medicine at Brigham and Women’s Hospital. Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. His clinical training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine.

After completing his training, Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He rose to the rank of Associate Professor of Medicine, Chief of Cardiology at the West Roxbury Veterans Administration Medical Center, and Director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital. He joined the faculty of Boston University in 1994, first as Chief of Cardiology and, in 1997, Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. He returned to Harvard and Brigham and Women’s Hospital in 2005 as the Hersey Professor of the Theory and Practice of Medicine, and Soma Weiss, M.D., Distinguished Chair in Medicine at Harvard Medical School, Chair of the Department of Medicine, and Physician-in-Chief at Brigham and Women’s Hospital. He transitioned from Department Chair in 2022 to his current roles.

Dr. Loscalzo is recognized as an outstanding cardiovascular scientist, clinician, and teacher. He has received many awards, including the Clinician-Scientist Award, the Distinguished Scientist Award, the Research Achievement Award, a MERIT Award, the Paul Dudley White Award and the Gold Heart Award from the American Heart Association; a Research Career Development Award, a Specialized Center of Research in Ischemic Heart Disease Award, and a MERIT Award from the National Institutes of Health; the George W. Thorn Award for Excellence in Teaching at Brigham and Women’s Hospital, the Educator of the Year Award in Clinical Medicine from Boston University, and the William Silen Lifetime Achievement in Mentorship Award from Harvard Medical School; the Glaxo Cardiovascular Research Award, the Rector’s Silver Medal from the University of Rome, Sapienza, and the Outstanding Investigator Prize from the International Society for Heart Research; election to fellowship in the American Association for the Advancement of Science, and in the American Academy of Arts and Sciences; and election to the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. He holds three honorary degrees. Castle Connolly has named him one of America’s Top Doctors over many years. He served as an associate editor of the New England Journal of Medicine for nine years, Chair of the Cardiovascular Board of the American Board of Internal Medicine, Chair of the Research Committee of the American Heart Association, Chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in the Cardiovascular Sciences, and Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of Health. He is a former member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a former member of the Council of Councils of the National Institutes of Health. He is currently Director of the NIH-funded Center for Accelerated Innovation (the Boston Biomedical Innovation Center), and of the NIH-funded Harvard Undiagnosed Disease Network program. He is also former Editor-in-Chief of Circulation, currently Editor-at-Large of the New England Journal of Medicine, and a current senior editor of Harrison’s Principles of Internal Medicine.

Dr. Loscalzo has been a visiting professor at many institutions, holds three honorary degrees, has authored or co-authored over 1,200 scientific publications (over 145,000 citations, h-index 174), has authored or edited 54 books, and holds 33 patents for his work in the field of nitric oxide, redox biology, and vascular biology. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis, atherosclerosis, and, more recently, systems biology over the past thirty years. His most recent work has established the field of network medicine, a paradigm-changing discipline that seeks to re-define disease and therapeutics from an integrated perspective using systems biology and network science.

Michael Mendelsohn, MD

Dr. Mendelsohn is the Founder, Chairman of the Board, and Chief Strategy Officer of Cardurion Pharmaceuticals, a clinical-stage cardiovascular biotechnology company. He is an internationally recognized cardiovascular physician-scientist, industry research leader and business executive with broad experience in healthcare.

Currently, Dr. Mendelsohn serves as a Board Director for Foghorn Therapeutics (FHTX) and Cyclerion Therapeutics (CYCN), and a Senior Advisor and consultant to the head of R&D at Takeda Pharmaceuticals. He is also a Professor of Medicine at Tufts University School of Medicine. From 2013-2017, Dr. Mendelsohn was a Venture Partner at SV Health Investors in Boston.

From 2010-2013, Dr. Mendelsohn served as SVP and Global Head of Cardiovascular Diseases at Merck & Co., with end-to-end responsibilities for cardiovascular scientific strategy, research & development, business development and customer engagement. In this role, he had responsibility for all cardiovascular research, from early drug discovery through late clinical development. At Merck, Dr. Mendelsohn directed preclinical and clinical programs in four major CV areas: heart failure, atherosclerosis, specialty hypertension, and thrombosis. He also worked closely with Merck’s Global Human Health division to align Merck’s research and commercial marketing, and with Merck business development to source, evaluate and advance a wide variety of partnerships and licensing agreements, including the worldwide joint venture between Merck and Bayer involving soluble guanylate cyclase (sGC) stimulator drugs.

Prior to Merck, Dr. Mendelsohn worked for 25 years as an academic cardiovascular physician-scientist in Boston. Dr. Mendelsohn received an undergraduate degree in Chemistry and English from Amherst College in 1978, and his MD from Harvard Medical School (HMS) in 1982. From 1982 to 1993, he completed a residency in internal medicine and from 1985-1988, a fellowship in cardiovascular medicine at the Brigham and Women’s Hospital (BWH) and HMS. He then spent five years as an assistant professor of medicine on the faculty of HMS, where he was a member of the BWH Cardiology Division and ran an independent, NIH-funded basic science laboratory focused on molecular cardiovascular biology.

In 1993, Dr. Mendelsohn moved to Tufts Medical Center, where he created and served as the first executive director of the Molecular Cardiology Research Institute, a research department of 18 faculty and approximately 120 members exploring basic and translational research in heart and vascular diseases. Dr. Mendelsohn was the first recipient of the Elisa Kent Mendelsohn Professorship of Molecular Cardiology and Medicine at Tufts University School of Medicine and in 2008, Dr. Mendelsohn was named the first-ever Chief Scientific Officer at Tufts.

As an academic physician-scientist, Dr. Mendelsohn focused on signal transduction pathways regulating vascular and myocardial function. His laboratory at Tufts contributed to deciphering the mechanisms of action of endogenous vascular protective molecules, including key pathways implicated in cardiovascular disease, with an emphasis on cyclic GMP signaling pathways in blood vessels and heart and on nuclear hormone receptor actions in the vasculature. He has been the principal investigator on numerous National Institutes of Health awards, including a Specialized Center of Research (SCOR) in Ischemic Heart Disease, a Program Project Grant (PPG) studying molecular mechanisms of vascular relaxation, and multiple RO1 awards.

Dr. Mendelsohn has served broadly on the editorial boards of research publications and has published over 150 peer-reviewed articles on numerous cardiovascular scientific and clinical topics. He was an invited speaker for the 1999 Nobel Symposium in Karlskoga, Sweden, “Estrogen and Women’s Health” and for the 2008 Nobel Symposium in Stockholm, “Recent Advances in Understanding Estrogen Signaling”. He is an elected member of the American Society of Clinical Investigation (ASCI), the Association of University Cardiologists (AUC) and the Association of American Physicians (AAP).

Eric A. Rose, MD

Chairman, Longview Ventures

Eric Rose, MD is an academic physician and entrepreneur with interests in drug discovery, biodefense, clinical evaluative research and health policy. From 2007 through 2020 he served as CEO and board chair of SIGA Technologies developer of anti-viral drugs directed at potential agents of bioterror. In 2008, he assumed the chairmanship of the Department of Health Policy at the Mount Sinai School of Medicine. From 1994 through 2007, he served as Surgeon in Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons, where he held a distinguished professorship. An accomplished heart surgeon, researcher and entrepreneur, Dr. Rose grew one of the nation’s premier departments of surgery while managing, investigating and developing complex medical technologies ranging from heart transplantation and novel approaches to Alzheimer’s disease to bioterrorism.

He has authored or co-authored more than 300 scientific publications which have been cited more than 5000 times and has received more than $100 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984, and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He served on the board of directors of Abiomed from 2008 until its sale to Johnson and Johnson in 2022 for $17 billion. Siga’s oral smallpox antiviral drug was approved by the FDA in 2019, with more than $1 billion in sales to the US Strategic National Stockpile. He has served on the board and more recently as Chief Medical Officer at Mesoblast, a company founded by Silviu Itescu MD in Rose’s lab at Columbia. A public company with a market capitalization of $1 billion, Mesoblast has pioneered the use of off-the-shelf mesenchymal lineage stem cells in multiple diseases and anticipates the first FDA approval for such cells to treat graft versus host disease in children who have received allogeneic bone marrow transplants with a PDUFA date in early January, 2025.

In 2011, Dr. Rose himself was diagnosed with multiple myeloma, treated with chemotherapy and autologous bone marrow transplantation, and remains in remission for more than 13 years. He was diagnosed with Parkinson’s Disease and has been treated with Deep Brain Stimulation.

He received both his undergraduate and medical degrees from Columbia University.

Teo Dagi, MD

T Forcht Dagi, MD, DMedSc, DHC, MBA, FRCSEd, FAANS, FACS, FCCM is a neurosurgeon and neuro-intensivist, a veteran venture capitalist and board director with extensive international experience in public service. He has helped raise over $700 million in funds for portfolio companies and venture capital funds and has more than 15 years of successful experience in founding, managing and exiting companies in health care services and in the life sciences. He has operating experience in healthcare services, healthcare information technology and the biomedical sector, and he has served on boards of directors of publicly traded and privately held companies including. His portfolio has included AtheroGenics, Inc (Nasdaq: AGIX); Inhibitex, Inc. (Nasdaq: INHX, acquired by Bristol-Myers-Squibb); Synageva, Inc. (acquired by Alexion); Trivirix, Inc. (acquired by Nortel); Encelle, Inc. (acquired by Pioneer Surgical); Teladoc (NYSE: TDOC); and Merix Biosciences (now Argos Therapeutics, Nasdaq: ARGS). He has also chaired or served on the scientific advisory boards of Dupont Pharma, Lundbeck, the Royal Bank of Canada and other private and publicly listed companies.

Dr. Dagi serves as an Honourary Professor at Queen’s University Belfast, Northern Ireland (UK), and a Scholar in the Academy at Harvard Medical School. He is past chair of the International Advisory Panel of the Queen’s School of Medicine. He is immediate past chair, and a Director of the Committee on Perioperative Care of the American College of Surgery the Council for Surgical and Perioperative Safety and the Anesthesia Patient Safety Foundation. He has lectured in the Harvard Business School on healthcare innovation and in the Biomedical Entrepreneurship Program at the Harvard-MIT Program in Health Sciences and Technology. He is Director of Life Sciences at Anglo Scientific at the Royal Institution of Great Britain.

Dr. Dagi received an AB from Columbia University, his MD and MPH degrees from Johns Hopkins, and an MBA from the Wharton School. He was named the Joseph P. Kennedy, Jr., Fellow at Harvard, from which he also received a MTS (jurisprudence). He trained at the Massachusetts General Hospital and the Neurosurgical Unit of the Guy’s, Maudsley and King’s College Hospitals in London, and was a Mendeleyeff Travelling Fellow and a Neuroresearch Foundation Fellow. He worked at the MGH Limbic Diencephalic Laboratory on neuromodulation, and at the NIH on PET scanning under Dr. Louis Sokoloff in the Laboratory for Cerebral Metabolism. He was appointed to the Reserve Council of the United States, and served as a neurosurgeon at the Walter Reed Army Medical Center, combat neurosurgeon and flight surgeon, and faculty in the John Fitzgerald Kennedy School for Special Warfare and the Uniformed Services University of the Health Sciences. He is a fellow of the American Association of Neurological Surgeons, the American College of Surgeons, for which he serves as a spokesman, and, by election, to the College of Critical Care Medicine, reserved for the highest 5% of practitioners in the field.

Dr. Dagi was President of the Georgia Neurosurgical Society, Director of the Georgia Biomedical Association, Founding Director of the Southeast Life Sciences Investor Association, Director of the Medical Development Group in Massachusetts and a Director of the American Association of Neurological Surgeons. He serves as an overseer of the Beth Israel Deaconess Medical Center in Boston and sits on the Research Oversight Committee. Among other distinctions, he has been awarded the US Humanitarian Service Medal, and a DMedSc from Queen’s University Belfast, and a DHC from the Kaunas Technical University in Lithuania for contributions to medicine and public service. He was named the Sir Thomas and Edith Dixon Medalist for 2012 and was named to an ad hominem Fellowship in the Royal College of Surgeons Edinburgh in 2013. In 2015 he was the Distinguished Lecturer in the Space 4 Biomedicine Program of the National Space Biomedical Research Institute (NSBRI) and the Baylor College of Medicine Center for Space Medicine. In 2016 he was named to the advisory board of CURAM, the Science Foundation Ireland Centre for Research in Medical Devices in Galway, Ireland. He is an editor of Neurosurgery, the Journal of Clinical Ethics, and Numanities, and has authored or co-authored over 175 articles and authored or edited several books.

Viviany R. Taqueti, MD, MPH, FACC, FAHA

Viviany Taqueti, MD, MPH is a cardiologist, clinical investigator and Director of the Cardiac Stress Laboratory at Brigham and Women’s Hospital and Harvard Medical School. She is also Director of Cardiometabolic and Physiologic Imaging at the Baim Institute for Clinical Research and Advisor at Broadview Ventures. She has expertise in cardiometabolic, ischemic and inflammatory heart disease. Her research applies multimodality imaging technology to quantify coronary blood flow, atherosclerotic plaque, microvascular dysfunction and body composition to redefine risk across patients with obesity and cardiometabolic disease.

Over a decade on faculty at Harvard Medical School, Dr. Taqueti pioneered the role of residual inflammation, coronary microvascular dysfunction and skeletal muscle adiposity on adverse cardiovascular outcomes, including heart failure with preserved ejection fraction, in patients with cardiovascular kidney metabolic syndrome. Her work has facilitated clinical translation of advanced imaging biomarkers in the evaluation of heart disease and the development of national and international evidence-based guidelines for diagnosis of coronary microvascular dysfunction in patients with chronic coronary disease.

Viviany is a physician-scientist, collaborative leader and strategic thinker with a global perspective. She graduated summa cum laude from Harvard University in biochemical sciences, magna cum laude from Harvard Medical School through the Harvard-MIT Division of Health Sciences and Technology, and completed internal medicine and cardiovascular disease and imaging training at Mass General Brigham. She has a Master from the Harvard School of Public Health and executive leadership training from Harvard Business School. She is board certified in Internal Medicine, Cardiovascular Disease, Echocardiography and Nuclear Cardiology. She is an elected member of the Faculty Council at Harvard Medical School and associate member at the Broad Institute of MIT and Harvard. A former editorial assistant at The New England Journal of Medicine, she is immediate past-Chair of the Scientific Publications Committee of the American College of Cardiology where she oversaw expansion to the 10-member JACC Journal portfolio and Chairs the Digital Transformation Committee with a $19 million strategic project budget. She is on the Board of Directors of the American Society of Nuclear Cardiology, the Editorial Board of the European Heart Journal and has served on writing committees for the AHA/ACC Guidelines and the National Academy of Medicine. Her research is supported by federal and foundation grants and has been published in top academic journals including The New England Journal of Medicine, Circulation, European Heart Journal, JAMA: Cardiologyand the Journal of the American College of Cardiology. She is an experienced member of Data Safety Monitoring Boards and Clinical Endpoint Adjudication Committees for major multicenter cardiovascular outcomes trials, and a frequent invited national and international speaker. She was born in Vitoria, Brazil, and spent her early years in Brazil’s northern Amazon region and Connecticut.

Investment Team

Strategic Advisory Board

Advisors